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Abstract Nonsurgical management of patients with symp-
tomatic mitral valve stenosis has been established as the
therapeutic modality of choice for two decades. Catheter-
based balloon dilation of the stenotic valvular area has been
shown, at least, as effective as surgical interventions.
Unfavorable results of catheter-based interventions are
largely due to unfavorable morphology of the valve
apparatus, particularly leaflets calcification and subvalvular
apparatus involvement. A mitral valve score has been
proposed in Boston, MA, about two decades ago, based on
morphologic assessment of mitral valve apparatus by two-
dimensional (2D) echocardiography to predict successful
balloon dilation of the mitral valve. Several other scores
have been developed in the following years in order to
more successfully predict balloon dilatation outcome.
However, all those scores were based on 2D echocardiog-
raphy, which is limited by ability to distinguish calcification
and subvalvular involvement. The introduction of new
matrix-based ultrasound probe has allowed 3D echocardi-
ography (3DE) to provide more detailed morphologic
analysis of mitral valve apparatus including calcification
and subvalvular involvement. Recently, a new 3DE scoring
system has been proposed by our group, which represents
an important leap into refinement of the use of echocardi-
ography guiding mitral valve interventions.
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Introduction
Although the incidence of rheumatic fever and its complica-
tions have declined in developed countries, the disease is still
a major health problem in many developing countries. The
mitral valve (MV) is the most commonly and severely
affected (65%–70% of patients) by rheumatic process by
stenosis and/or regurgitation [1]. Percutaneous balloon mitral
valvuloplasty (BMV) was introduced in 1984 by Inoue et al.
[2￿￿] for the treatment of selected patients with mitral
stenosis. BMV is a minimally invasive, nonsurgical proce-
dure that has been established in several clinical studies to be
a safe and effective therapeutic modality in selected patients
with mitral stenosis (MS) [3–5] and is equivalent to or even
better than surgical commissurotomy [6, 7]. With successful
BMV , there is generally a twofold increase in the mitral valve
area and an associated dramatic fall in transmitral valve
gradient, left atrial pressure, and pulmonary artery pressure
[3, 4, 8, 9]. These hemodynamic benefits are associated with
postprocedural improvement in the patients’ symptoms and
exercise tolerance [10]. The safety and success of BMV
techniques is mostly dependent on the selection of patients.
There are multiple predictors of the outcome, including age,
functional class, previous commissurotomy, preprocedure
MV area, valve anatomy, and balloon size used [11].
Morphology of the MV is considered as the main predictor
of a successful BMVand hence MV scoring system using
echocardiography is of crucial importance [11]. Many scores
are derived targeting patient selection before BMV and
correlated the severity with the immediate and long-term
outcome. In this review article, we will summarize main
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MVAnatomy and Pathology
The MV is highly complex structure made up of several
individual parts which need to function in harmony to
maintain its competency. The parts are the annulus, the
leaflets,thechordaetendineacords,andthepapillarymuscles.
The most important component of the valve is the leaflets.
Anatomistsusuallydescribedthetwoleafletsasbeinganterior
and posterior. However, the appropriate orientation of the MV
is seen to occupy a more oblique position within the cardiac
short axis than these traditional names suggest. When the
valve is closed, both leaflet edges form an arc-shaped closure
line that is obliquely situated relative to the orthogonal planes
of the body. Both ends of closure line are referred to as
commissures (anterolateral and posteromedial). The antero-
lateral commissure is next to the left fibrous trigone and the
left atrial appendage, while the posteromedial commissure is
next to the right fibrous trigone and the interatrial septum.
From the usual practice of the pathologist and anatomist, each
leaflet is divided by indentations into three unequal segments,
the so-called “scallops” [12–14].
Chordae tendineae are string-like structures that take
origin from the papillary muscles, bifurcate several
t i m e s ,a n da t t a c ht ot h ev e n t r i c u l a ra s p e c t so fb o t h
leaflets. The cords are thinnest at their sites of insertion
on the leaflets. Primary cords normally insert in uniform
fashion along the free margin of both leaflets. Secondary
cords insert in layered fashion along the rough zone of
the anterior leaflet. The coapting surfaces meet during
systolic closure. As the papillary muscles contract and
relax, the chordae tendineae transmit the resulting
increase and decrease in tension to the MV causing
open and closure [14, 15].
The characteristic lesion of acute rheumatic fever is the
Aschoff body, consisting of necrotic foci surrounded by
activated histiocytes and lymphocytes and ultimately heals by
fibrosis. These foci may be found in the pericardium, the
myocardium, or in the valves. Chronic cardiac manifestations
include fibrocalcific valvulitis [16]. Chronic rheumatic
affection of the MV leaflets especially with recurrent
episodes includes chronic scarring. Chronic scarring of the
valve leaflets converts a translucent, pliable valve into a stiff,
thickened structure and leads to one or all of the following
deformities:
& Fusion of the leaflet commissures.
& Thickening, fibrosis, and calcification of the leaflet cusps.
These changes become progressive over time and result
in funnel-shaped stenotic MV , which is often called “fish
mouthed.” Rheumatic involvement of subvalvular appara-
tus includes fusion, thickening, retraction, shortening, and
calcification. As a consequence, the free interchordal space
diminishes and the opened “leaflet–chordae tendineae
tunnel” available for diastolic flow is limited [16].
Percutaneous Balloon Mitral Valvuloplasty
Since the advent of the Inoue balloon in 1984 [2￿￿], BMV
became a feasible option for many patients with symptom-
atic MS. During BMV , the balloon is introduced across the
mitral valve and its inflation fractures the rheumatic fusion
of the valve leaflets at the commissures, dramatically
improving leaflet excursion and orifice area [17]. Numerous
large series have reported excellent short, medium, and
long-term outcome with a low incidence of serious
complications [18].
Randomized trials comparing BMV to closed com-
missurotomy show it to be superior to closed commis-
surotomy, providing an often larger valve area and
exhibiting excellent long-term durability. In patients with
MV score ≤8 (see later) and sinus rhythm, both BMVand
open commissurotomy were comparable [19].
Metallic valvulotome achieved encouraging results with
the reduction of the procedure cost [20, 21￿￿]. BMVis now
the treatment of choice for many patients with symptomatic
mitral stenosis. Applications are expanding to include
several categories of patients previously considered ineligi-
ble for the procedure [22].
MV Scoring Systems by Two-Dimensional
Echocardiography
Transthoracic two-dimensional echocardiography (2DE)
allows classification of patients into anatomic groups to
predict immediate and long-term outcome of BMV . Several
2DE scoring systems have been suggested for evaluation of
MV anatomy. Wilkins scoring system evaluates leaflet
thickening, mobility, calcification, and subvalvular involve-
ment on a scale of 0–4( T a b l e1)[ 23￿￿]. The MV
morphology is considered favorable if the mitral echocar-
diographic score is ≤8.
Another 2DE score by Chen et al. [24] is a modified
Wilkins score parameter for subvalvular thickening accord-
ing to the involved segment of chordal length: (1) if less
than 1/3, (2) if more than 1/3, (3) if more than 2/3, and (4)
if involved the whole chordal length with no separation.
Reid score includes leaflet motion, leaflet thickness,
subvalvular disease, and commissural calcium. Leaflet
motion was expressed as a slope by dividing the height
(H) by the length (L) of doming of anterior leaflet. Leaflet
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of the tip of MVand thickness of posterior wall of aortic
root. The score was assigned as 0 for mild affection, 1 for
moderate, and 2 for severe affection [25￿].
Nobuyoshi score included leaflet pliability, commissural
disease, and subvalvular apparatus (Table 2)[ 26￿].
Cormier score divided the patients into three groups
depending on leaflets mobility and calcification and
subvalvular affection: group 1, pliable noncalcified anterior
mitral leaflet and mild subvalvular disease (i.e., thin
chordae >10 mm long); group 2, pliable noncalcified
anterior mitral leaflet and severe subvalvular disease (i.e.,
thickened chordae <10 mm long); and group 3, calcification
of MVof any extent, as assessed by fluoroscopy, whatever
the state of subvalvular apparatus [27].
However, none of the available 2DE scores has been
shown to be superior to any of the others [28]. Most
cardiologists use the Wilkins score. The available scoring
systems, particularly Wilkins score, have many limitations
[22, 29, 30], including:
& Echocardiography limited in ability to differentiate
nodular fibrosis from calcification.
& Assessment of commissural involvement is not included
or underestimated.
& Doesn’t account for uneven distribution of pathologic
abnormalities.
& Doesn’t account for relative contribution of each
variable (no weighting of variables).
& Frequent underestimation of subvalvular disease.
& Doesn’t use results from TEE or 3D echocardiography.
An ideal echo scoring system has to have many criteria:
& Global and segmental evaluation (qualitative and
quantitative) of each MV apparatus component sepa-
rately to localize the deformity in a specific portion of
MVapparatus.
& Inclusion of all points that proved to predict and affect
the PMVoutcome via large study.
& V alidation in large studies that include patients with
different age groups (not only young).
& Easily applicable and interpretable by most cardiolo-
gists within a reasonable time.
& High reproducibility and reliability.
& Unified for both transthoracic and transesophageal
approaches.
Table 1 Grading of mitral valve characteristics from the echocardiographic examination according to Wilkins (Boston) score
Grade Mobility Thickening Calcification Subvalvar thickening
1 Highly mobile valve with
only leaflet tips restricted
Leaflets near normal in
thickness (4–5 mm)
A single area of
increased echo
brightness
A single area of increased echo brightness
2 Leaflet mid and base
portions have normal
mobility
Mid-leaflets normal,
considerable thickening of
margins (5–8 mm)
Scattered areas of
brightness confined to
leaflet margins
Scattered areas of brightness confined to
leaflet margins
3 V alve continues to move
forward in diastole,
mainly from the base
Thickening extending
through the entire leaflet
(5–8 mm)
Brightness extending
into the mid-portion of
the leaflets
Thickening extending to the distal third of
the chords
4 No or minimal forward
movement of the leaflets
in diastole
Considerable thickening of
all leaflet tissue (>8–
10 mm)
Extensive brightness
throughout much of
the leaflet tissue
Extensive thickening and shortening of all
chordal structures extending down to the
papillary muscles
(Modified from Wilkins et al. [23￿￿]; with permission.)
Component Score Definition
Leaflet mobility 1 Pliable leaflets with minimal restriction of leaflet tip mobility
2 Semi-pliable leaflets with restriction of leaflet body mobility
3 Minimal forward movement of the leaflets
Commissural disease 1 No commissural disease
2 One commissural disease
3 Both commissural disease
4 Diffuse commissural disease
Subvalvular disease 1 Minimal thickening of chordae
2 Thickening and shortening of chordae
3 Fused subvalvular apparatus
Table 2 Nobuyoshi score
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Echocardiography
Three-dimensional echocardiography (3DE) has established
a clear understanding of the functional anatomy of the MV .
Real-time 3DE (RT3DE) provided detailed morphologic
display and analysis of the mitral valve apparatus in 3D
(Fig. 1). In addition, RT3DE provided rapid, accurate
quantification of mitral valve structure, particularly for
determining the valvular orifice area, as it facilitates the
orientation of any slice plane to locate the minimal MV
area. The improvement of RT3DE probe technology,
especially the latest innovation in transesophageal (Fig. 2)
3DE probes, raised the need to construct a scoring system
using RT3DE because it can be used independently before,
during, and after BMV .
MV Score by 3DE
Recently, Anwar et al. [31￿￿] introduced the first scoring
system using real-time transthoracic 3DE (RT3D-TTE) in
patients with MS candidate for BMV . The authors compared
the RT3D-TTE score with Wilkins score regarding the
selection of patients through the PMVoutcome [31￿￿].
Description
The new RT3DE morphology score was derived to include
both MV leaflets and subvalvular apparatus (Table 3).
Scoring of Leaflets
Each leaflet was divided into three scallops (anterolateral
A1–P1, middle A2–P2, and posteromedial A3–P3) and
scored separately for thickness, mobility, and calcification.
Thickness, mobility, and calcification for each scallop were
scored as follows: normal thickness and mobility was
scored as 0, and abnormal thickness or restricted mobility
was scored as 1. Absence of calcification was scored as 0,
calcification in middle scallop (A2 or P2) was scored as 1,
and calcification of commissural scallops of both leaflets
(A1, A3–P1, P3) was scored as 2. Figure 3 displays an
example of leaflets thickening on RT-TT3DE in a patient
with rheumatic heart disease.
Scoring of Subvalvular Apparatus
The anterior and posterior chordae were scored at three
levels: proximal (valve level), middle, and distal (papillary
muscle level). At each level, both anterior and posterior
Fig. 2 An example of mitral valve stenosis seen from left ventricular
side on transesophageal RT-3DE
Fig. 1 An example of rheumatic mitral valve stenosis as seen from
left atrial side (a) and left ventricular side (b)
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in between as follows: normal thickness was scored as 0
and abnormal thickness was scored as 1, normal chordal
separation (distance in between >5 mm) was scored as 0,
partial separation (distance in between <5 mm) as 1, and
absence of separation as 2. Figure 4 displays an example of
chordal thickening on RT-TT3DE in a patient with
rheumatic heart disease.
Total Score Grading
The individual RT3DE score points of leaflets and subvalv-
ular apparatus RT3DE score were summed to calculate the
total RT3DE score, ranging from 0 to 31 points. Total score of
mild MV involvement was defined as <8 points, moderate
MV involvement 8–13, and severe MV involvement >14.
Potential Advantages
The 3D score has many potential benefits that help for a
detailed assessment of the MV .
1. Visualization of leaflets. By RT3DE, visualization and
assessment of the whole length of both leaflets is
possible through single image plane, especially in sinus
rhythm. Leaflet mobility could be well assessed.
RT3DE could detect the thickness of each leaflet
scallop. The whole leaflet length could not be evaluated
by a single 2DE image especially for the posterior
leaflet, which is short and naturally less mobile than the
anterior one. As shown in Table 4, many views from
different cut section planes are needed to assess all
scallops.
2. Leaflet calcification. Scoring of leaflet calcification
using Wilkins score depends on the bright areas and the
extension of calcification along the leaflet length [32,
33]. Multiple cut planes are needed for detecting
calcification in all scallops of both MV leaflets. RT3DE
could predict the extent and distribution of calcification
in each scallop from a single short axis cut plain. The
new RT3DE score described calcification at the
commissural parts of leaflet by a higher score than the
middle leaflets calcification because it was proved that
calcification of commissures is one of the strong
predictors of outcome after PMV because it affects
the degree of commissural splitting (Fig. 5)[ 34, 35].
3. Subvalvular apparatus. RT3DE score included the
chordal thickness and separation, which is a good
independent predictor for BMVoutcome. Both chordal
thickness and separation are scored at three levels by
Fig. 4 Displays an example of chordal thickening on RT-TT3DE in a
patient with rheumatic heart disease
Fig. 3 Displays an example of leaflets thickening on RT-TT3DE in a
patient with rheumatic heart disease
Leaflets
Anterior leaflet Posterior leaflet
A1 A2 A3 P1 P2 P3
aThickness (0–6) 0–10 –10 –10 –10 –10 –1
aMobility (0–6) 0–10 –10 –10 –10 –10 –1
bCalcification (0–10) (0=no, 1–2=calcified) 0–20 –10 –20 –20 –10 –2
bSubvalvular apparatus
Proximal third Middle third Distal third
Thickness (0–3) (0=normal, 1=thickened) 0–10 –10 –1
Separation (0–6) (0=normal, 1=partial, 2=no) 0–20 –20 –2
Table 3 Mitral valve score
based on real-time three-
dimensional echocardiography
aNormal=0, mild=1–2, moder-
ate=3–4, severe >5
bNormal=0, mild=1–2, moder-
ate=3–5, severe >6
(Modified from Anwar et al.
[31￿￿]; with permission.)
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and distal). This detailed information, especially for
chordal separation, was not obtained by most 2D
scoring systems, including Wilkins score [36].
4. Score applicability. Compared to Wilkins score, the
RT3DE score is simple and more helpful, particularly
for less experienced operators as it provides a simple
number for each leaflet scallop and subvalvular
apparatus segment separately. This was evident by
good interobserver and intraobserver agreements for
most of the score components.
5. Score approach. The score can be applied using both
transthoracic andtransesophagealapproachesbecausethe
image orientation and interpretation are not different.
Limitations and Arguments of 3DE Mitral Score
The 3D technology is not available in all cardiac centers
and thus the lack of it is widespread. This is true; however,
all new techniques passed the same stages and by time the
new techniques gradually replace the old ones until the
stage of standardization, availability, and widespread use is
achieved.
The image acquisition, cut sections, and dealing with the
analysis software are operator dependent to a high extent.
However, the probe position and acquisition is easy for any
echocardiographers.Inaddition,thosedealingwiththeanalysis
software need training to be familiar and get the experience.
Most cardiologists are aware with the 2D images and
interpretation of Wilkins score. The need for learning time
to develop the experience with 3D technology is a must.
The visual familiarity and mental conception of the
cardiologists toward the 2D images are very helpful to
build the experience with 3D.
The available 3D score is more complex and time
consuming. This is due to many anatomical and morpho-
logical components included to achieve a detailed assess-
ment. Rapid technical improvements will overcome such a
limitation, and future studies may simplify this score.
The score is highly selective for the optimal result of BMV .
This means that a considerable percentage of patients are
groupedasnonfavorableorlessfavorableforBMVandwillbe
excluded. Therefore, more referral and exposure to surgical
intervention are needed. The decision to perform BMVis not
solely dependent on the MV score but the clinical judgment is
sharing. For example, in patients with an unacceptable high
risk for heart surgery, BMV can be preferred even with high
MV score with the need of patient and physician awareness
regarding the higher risk, the lower success rate, and
suboptimal long-term outcome of BMV . In general, the
selection of therapeutic modality to patient is always
dependent on risk/benefit ratio. Other factors may be
considered (e.g., age, functional class, patient preference, cost
and simplicity of procedure, associated other valve lesions,
and associated comorbidities) [22].
Personal Perspectives/Conclusions
Due to higher resolution and better image quality, RT3D-
TEE will save the time and minimize the cost to do many
echo studies (2D-TTE, 2D-TEE, and RT3D-TTE) for a
detailed assessment of MV morphology before BMV . The
application of the 3D scoring system will be obtainable in
all patients regardless of their transthoracic image quality
and underlying heart rhythm.
At the start of learning, both the new RT3DE score and
Wilkins score can be used complementary to each other for
evaluation before BMV . This will facilitate future standard-
ization of RT3DE for both quantitative and qualitative
assessment of the MV .
Large-scale studies from multiple centers are needed to
improve the applicability of 3D scoring. With the large
number of patients, BMVoutcome may direct the inves-
tigators to modify the available 3D score by adding or
omitting some of the score components. With this article,
Fig. 5 Displays an example of chordal splitting after balloon mitral
valvuloplasty on RT-TT3DE in a patient with rheumatic heart disease
Table 4 Observed scallop in each two-dimensional echocardiographic
view
View A1 A2 A3 P1 P2 P3
Parasternal long-axis − + −−+ −
Apical 4-chamber − +++−−
Apical 2-chamber + + −−+ −
Apical long-axis − + −−+ −
Parasternal short-axis ± + ± + + +
+, visualized; −, not visualized; ±, may be visualized
Curr Cardiovasc Imaging Rep (2011) 4:370–377 375we hope to encourage investigators and stimulate them to
develop scientific studies to achieve establishment and
standardization of the ideal 3D score. We expect that in the
near future, assessment of MV by the ideal 3D score will be
widely used as a stand-alone modality.
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